parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in lymphatic endothelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13024

PLSCR4 in dopamine neurons, braak+0.52 (p 0.151) → +0.50 (p 0.173)receipt 13032
PLSCR4 in astrocytes, braak-0.42 (p 0.265) → +0.33 (p 0.386)receipt 13031

receipt 13032: PLSCR4 in dopamine neurons, braak

power: full sample +0.42 (p 0.084, n 18), 95% CI -0.06 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.41 (p 0.095, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.107, n 18). could be the mix.
skeptic: leave-one-out range +0.35 to +0.60, sign flips 0; without severely affected donors +0.42 (p 0.084, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PLSCR4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13031: PLSCR4 in astrocytes, braak

power: full sample -0.01 (p 0.976, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.671, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.579, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.15, sign flips 9; without severely affected donors -0.01 (p 0.976, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PLSCR4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts